Valeant Pharma (VRX) Ramps to Session Highs Following Analyst Upgrade
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Valeant's (VRX) Amended Facility Expected, But Shares Remain Uninvestible - Piper
August 19, 2016 6:39 AM EDTPiper Jaffray affirms Valeant Pharma (NYSE: VRX) with an Underweight rating and $22 price target following news that the company entered an amended credit facility.
Analyst David Amsellem commented today:
Valeant shares have been strong of late, ostensibly in anticipation of an amendment to the companys credit facility (which was announced on Thursday) that gives the company more breathing room as it looks to stabilize and turn around key segments and sell off non-core assets... More
RBC Capital Remains Sidelined as Valeant Pharma (VRX) Announces Credit Amendment
August 18, 2016 11:15 AM EDTRBC Capital reiterated a Sector Perform rating and $36.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announcement that is has agreed to amend terms with its lenders. This decision comes on the heels of VRX's Aug 12th announcement that the company would... More
Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley
August 17, 2016 7:03 AM EDTValeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanleys upgrade to Overweight and raising its price target to $42 from $33.
... MoreMorgan Stanley Makes Bullish Call on Valeant (VRX); Rating Raised to 'Overweight'
August 17, 2016 6:59 AM EDT(Updated - August 17, 2016 10:46 AM EDT)
Morgan Stanley upgraded Valeant Pharmaceuticals (NYSE: VRX) from Equalweight to Overweight with a price target of $42, implying 58% upside. The stock's bull case price target is $68 and its bear case is $11. Analyst David Risinger said his upgrade was primarily a multiple expansion call.
Risinger explained, "Although VRX still faces risks, we see the upside skew as attractive. Risk of severe financial stress... More
